


بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم


قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





Pattern of Tuberculosis in El Maamora Chest Hospital, Alexandria, Egypt, During the Period (2014-2018)

Thesis

*Submitted for Partial Fulfillment of Master Degree In
Chest Diseases*

By

Tamer Mohamed Salem

M.B.B.Ch, Faculty Medicine - Alexandria University

Under supervision of

Prof. Tarek Mohamed Aziz Safwat

Professor of Chest Diseases

Faculty of Medicine – Ain Shams University

Prof. Tamer Mohamed Ali

Professor of Chest Diseases

Faculty of Medicine – Ain Shams University

*Faculty of Medicine
Ain Shams University
2021*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبَّحَانَكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Tarek Mohamed Aziz Safwat**, Professor of Chest Diseases - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Tamer Mohamed Ali**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I present my deepest gratitude to my dear colleagues in **El maamora** Chest Hospital who supported me, supplied me with many important and up to date scientific materials and encouraged me for more and more hard and accurate work.*

*Finally, my great thanks extended also to **My Family** especially **My Wife** who beared a lot of hard times and encouraged me to finish this work successfully.*

Tamer Salem

List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	iii
List of Figures	v
Abstract	vii
Introduction	1
Aim of the Work.....	3
Review of Literature	
Tuberculosis.....	4
Epidemiology of Tuberculosis in Egypt	18
Complications of Tuberculosis.....	21
Diagnosis of Tuberculosis	37
Treatment of Tuberculosis	64
Patients and Methods.....	87
Results	92
Discussion	119
Summary	134
Conclusion	139
Recommendations	140
References	142
Arabic Summar	—

List of Abbreviations

Abb.	Full term
ADA	Adenosine deaminase
AFB.....	Acid-fast bacilli
APCs	Antigen-presenting cells
ART.....	Antiretroviral therapy
BCG	Bacillus-Calmette Guerin
BLT.....	Bone marrow, liver, thymic
CDC	Centers for Disease Control and Prevention
CNS	Central nervous system
DOTS.....	Directly Observed Treatment Short-Course
DST.....	Drug susceptibility testing
EPTB	Extrapulmonary tuberculosis
FDA	Food and Drug Administration
FNA	Fine needle aspiration
HIV	Human immunodeficiency
IFN- γ	Interferon-gamma
IGRA.....	IFN- γ releasing assay
IGRAs	Interferon-gamma release assays
IRIS	Immune reconstitution inflammatory syndrome
LED	Light-emitting diodes
LPA.....	Line probe assay
LTBI	Latent tuberculosis infection
MDR	Multidrug-resistant
MHC	Major histocompatibility complex
MLN	Mediastinal lymph node
MTB.....	Mycobacterium tuberculosis

List of Abbreviations Cont...

Abb.	Full term
NAA	Nucleic acid amplification
NAAT.....	Nucleic acid amplification test
NAT2	N-acetyltransferase
NTM	Nontuberculous mycobacterial
PAMPS	Pathogen-associated molecular patterns
PCR.....	Polymerase chain reaction
PRRs	Pattern recognition receptors
PTB.....	Pulmonary TB
Rpf	Resuscitation-promoting factor
SIV	Simian immunodeficiency virus
TA	Toxin-antitoxin
TB	Tuberculosis
TB-LAM.....	TB lipoarabinomannan
TDM.....	Therapeutic drug monitoring
TLRs	Toll-like receptors
TST	Tuberculin skin test
WHO	World Health Organization

List of Tables

Table No.	Title	Page No.
Table (1):	Selected acute and chronic TB related complications, by site.....	29
Table (2):	Tuberculosis Drugs, Recommended Dosages, and Common Adverse Events	74
Table (3):	Socio-demographic data among 1413 TB patients:.....	92
Table (4):	Clinical data among 1413 TB patients:.....	93
Table (5):	Clinical presentations and comorbidities among 1413 TB patients:.....	96
Table (6):	Investigations data among 1413 TB patients.	98
Table (7):	Treatment data among 1413 TB patients:.....	100
Table (8):	Outcome data among 1413 TB patients:.....	101
Table (9):	Comparison between the 3 groups as regards socio-demographic data using Kruskal-Wallis and Chi square tests:.....	103
Table (10):	Comparison between the 3 groups as regards clinical data using Chi square test:.....	104
Table (11):	Comparison between the 3 groups as regards clinical presentations and comorbidities using Chi square test:.....	106
Table (12):	Comparison between the 3 groups as regards investigations data using Chi square test:.....	108
Table (13):	Comparison between the 3 groups as regards treatment data using Chi square test:	110
Table (14):	Comparison between the 3 groups as regards outcome data using Kruskal-Wallis and Chi square tests:.....	112

List of Tables Cont...

Table No.	Title	Page No.
Table (15):	Logistic regression model for the Factors affecting successful seroconversion occurrence using Forward method:	117
Table (16):	Logistic regression model for the Factors affecting improvement occurrence using Forward method:	118
Table (17):	Logistic regression model for the Factors affecting deterioration occurrence using Forward method:	118

List of Figures

Fig. No.	Title	Page No.
Figure (1):	A 52-year-old man with severe pulmonary tuberculosis causing total fibrocavitary destruction of the left lung.....	35
Figure (2):	Biphasic Decline in Viable Bacteria during Treatment for Tuberculosis	66
Figure (3):	CT Scans of the Lung in a Patient with Pulmonary Tuberculosis	69
Figure (4):	Sites and Mechanisms of Action of Antimycobacterial Agents	85
Figure (5):	Year of admission among 1413 TB patients.....	94
Figure (6):	Patient category among 1413 TB patients.	94
Figure (7):	Localization of TB among 1413 TB patients.....	95
Figure (8):	Clinical presentations among 1413 TB patients.....	97
Figure (9):	Comorbidities among 1413 TB patients.....	97
Figure (10):	CXR affection side among 1413 TB patients.	99
Figure (11):	CXR affection severity among 1413 TB patients.....	99
Figure (12):	Treatment regimen among 1413 TB patients.....	100
Figure (13):	Patient outcomes among 1413 TB patients.....	102
Figure (14):	Comparison between the 3 groups as regards clinical data.	105
Figure (15):	Comparison between the 3 groups as regards sputum results (before tt).	109
Figure (16):	Comparison between the 3 groups as regards CXR affection severity.	109

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (17):	Comparison between the 3 groups as regards treatment regimen.....	111
Figure (18):	Comparison between the 3 groups as regards patient compliance.....	111
Figure (19):	Comparison between the 3 groups as regards time of sputum conversion to -ve (after ttt).....	113
Figure (20):	Comparison between the 3 groups as regards sputum conversion.....	114
Figure (21):	Comparison between the 3 groups as regards patient outcomes.	115
Figure (22):	Comparison between the 3 groups as regards deterioration rate.....	115

Abstract

Background: Tuberculosis is a major health problem, tuberculosis affects most of age groups, and this necessitates more attention in the tuberculosis (TB) control program targeting those age group. This study was carried out in El Maamora's chest hospital which is considered as the biggest chest hospital in Alexandria governorates, with a higher rate of outpatient clinic and admission so this study will give us a good analysis of the pattern of tuberculosis in Alexandria.

Objective: This study conducted to assess the TB pattern and to provide an insight into the type of TB infection in El Maamora's chest hospital.

Subjects: A total of 1413 TB patients were included in the study. We included patients diagnosed and treated as pulmonary tuberculosis (PTB), extrapulmonary tuberculosis (EPTB), patients with multidrug-resistant tuberculosis (MDR).

Methods: Data collected about patients included; full history taking, clinical and demographic characteristics, types of TB infection, affected organs, clinical presentations, methods of diagnosis, treatments, and outcomes were recorded.

Results: In the studied population, it was found that, the mean age of all patients was (39.5 ± 14.7) years, with the majority (79.3%) of patients were males; while (20.7%) were females. The average time of sputum conversion of all patients was (2.3 ± 0.8) months; with (51.2%) of patients had sputum conversion to -ve (after treatment). It was found that, (92.1%) improved or cured, (2.2%) had lost follow up, (0.4%) had ICU admission, (1.5%) suffered mortality, (0.8%) refused treatment. The improvement rate was (92.1%), and the deterioration rate (ICU admission and mortality) was (1.9%). There was a highly significant increase in time of sputum conversion in extra-pulmonary TB group; compared to other groups ($p < 0.01$). Comparative study between the 3 groups revealed a highly significant decrease in sputum conversion after treatment, in extrapulmonary TB group; compared to other groups ($p < 0.01$), and a highly significant increase in improvement rate in pulmonary and extrapulmonary TB groups; compared to MDR TB group ($p < 0.01$).

Conclusion: Tuberculosis (TB) is a global emergency posing a significant threat to people of all nations. Despite the advance of the DOTS program (Directly Observed Therapy Short Course), TB is still one of the leading causes of death worldwide particularly in developing countries, which have many patterns of infection as pulmonary, extrapulmonary, and MDRS.

Key words: Tuberculosis, prevalence, outcomes

INTRODUCTION

Tuberculosis is a contagious bacterial disease, that is a major health problem worldwide (*WHO, 2020*).

Despite being a potentially curable disease, tuberculosis is the second leading infectious cause of death worldwide (after AIDS), killing around 2 million people per year. Tuberculosis can attack people of any sex, age, or socioeconomic class (*Organization, 2005*).

In reality, tuberculosis is likely to claim its greatest toll from strata of the population, and it is important to identify these for planning and implementing TB control (*Chapman et al., 2014*).

In 2014, there were an estimated 9.6 million new TB cases, more than 90% of the new cases and deaths occurs in developing countries.

Egypt has massively engaged in early case detection, provision of adequate chemotherapy, and prevention of transmission to new cases (*WHO, 2013*).

The prevalence of TB in Egypt was 26 per 100.000 people according to the world health organization estimate in 2014, while the incidence rate of 15 per 100.000 people (*WHO, 2015*).